EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Polystyrene microplastics induces the injury of human corneal epithelial cells through ROS-mediated p53 pathway

Jianfeng Long, Limin Deng, Jian Liu, Kang Zhou, Shijie He

Mutagenesis · 2026-10-27 · 41 (6) · 311-319

DOI: 10.1093/mutage/geaf011 ↗
AbstractBibliografische Angaben

Abstract

Abstract This study aimed to investigate the effects of polystyrene microplastics (PS-MPs) on human corneal epithelial cells (HCEP). The cytotoxicity of PS-MPs on HCEP cells was evaluated using a CCK-8 assay to measure cell viability, flow cytometry to analyze cell cycle and status, immunofluorescence to detect reactive oxygen species (ROS) and γ-H2AX levels, and western blotting to assess protein expression. The effects of PS-MPs on HCEP cell morphology and viability were particle size- and concentration-dependent. Smaller particle sizes and higher concentrations of PS-MPs were associated with greater cytotoxicity. PS-MP exposure induced cell cycle arrest, necrosis, and apoptosis in HCEP cells, along with excessive ROS production and DNA damage. Furthermore, ROS scavengers significantly reduced PS-MP-induced ROS overproduction and DNA damage, thereby alleviating PS-MP-induced cell cycle arrest, necrosis, and apoptosis. At the molecular level, ROS scavengers reversed the PS-MP-induced changes in the expression of γ-H2AX, P53, cell cycle-related proteins (cyclin D1, CDK2, and CDK4), necrosis-related proteins (CypD, PARP-1, and SRX), and apoptosis-related proteins (Cyt C, AIF, and cleaved-caspase 3). PS-MP exposure leads to cell cycle arrest, necrosis, and apoptosis in HCEP cells, which is associated with ROS overproduction and activation of the P53 pathway.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →